- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
VRIO Analysis of PluroGen Therapeutics
Posted by Zachary Edwards on Mar-22-2018
The VRIO Analysis of PluroGen Therapeutics will look at each of its internal resources one by one to assess whether these provide sustained competitive advantage. The PluroGen Therapeutics VRIO Analysis also mentions at each stage whether these resources could be improved to provide a greater competitive advantage. Lastly, the resources analysed are summarised as to whether they offer sustained competitive advantage, has an unused competitive advantage, temporary competitive advantage, competitive parity or competitive disadvantage.
Valuable
- The PluroGen Therapeutics VRIO Analysis shows that the financial resources of PluroGen Therapeutics are highly valuable as these help in investing into external opportunities that arise. These also help PluroGen Therapeutics in combating external threats.
- According to the VRIO Analysis of PluroGen Therapeutics, its local food products are a valuable resource as these are highly differentiated. This makes the perceived value for these by customers high. These are also valued more than the competition by customers due to the differentiation in these products.
- The PluroGen Therapeutics VRIO Analysis shows that PluroGen Therapeutics's employees are a valuable resource to the firm. A significant portion of the workforce is highly trained, and this leads to more productive output for the organisation. The employees are also loyal, and retention levels for the organisation are high. All of this translates into greater value for the end consumers of PluroGen Therapeutics's products.
- According to the VRIO Analysis of PluroGen Therapeutics, its patents are a valuable resource as these allow the firm to sell its products without competitive interference. This results in greater revenue for PluroGen Therapeutics. These patents also provide PluroGen Therapeutics with licensing revenue when it licenses these patents out to other manufacturers.
- The PluroGen Therapeutics VRIO Analysis shows that PluroGen Therapeutics’s distribution network is a valuable resource. This helps it in reaching out to more and more customers. This ensures greater revenues for PluroGen Therapeutics. It also ensures that promotion activities translate into sales as the products are easily available.
- According to the VRIO Analysis of PluroGen Therapeutics, its cost structure is not a valuable resource. This is because the methods of production lead to greater costs than that of competition, which affects the overall profits of the firm. Therefore, its cost structure is a competitive disadvantage that needs to be worked on.
- The PluroGen Therapeutics VRIO Analysis shows that the research and development at PluroGen Therapeutics is not a valuable resource. This is because research and development are costing more than the benefits it provides in the form of innovation. There have been very few innovative features and breakthrough products in the past few years. Therefore, research and development are a competitive disadvantage for PluroGen Therapeutics. It is recommended that the research and development teams are improved, and costs are cut for these.
Rare
- The financial resources of PluroGen Therapeutics are found to be rare according to the VRIO Analysis of PluroGen Therapeutics. Strong financial resources are only possessed by a few companies in the industry.
- The local food products are found to be not rare as identified by PluroGen Therapeutics VRIO Analysis. These are easily provided in the market by other competitors. This means that competitors can use these resources in the same way as PluroGen Therapeutics and inhibit competitive advantage. This means that the local food products result in competitive parity for PluroGen Therapeutics. As this resource is valuable, PluroGen Therapeutics can still make use of this resource.
- The employees of PluroGen Therapeutics are a rare resource as identified by the VRIO Analysis of PluroGen Therapeutics. These employees are highly trained and skilled, which is not the case with employees in other firms. The better compensation and work environment ensure that these employees do not leave for other firms.
- The patents of PluroGen Therapeutics are a rare resource as identified by the PluroGen Therapeutics VRIO Analysis. These patents are not easily available and are not possessed by competitors. This allows PluroGen Therapeutics to use them without interference from the competition.
- The distribution network of PluroGen Therapeutics is a rare resource as identified by the VRIO Analysis of PluroGen Therapeutics. This is because competitors would require a lot of investment and time to come up with a better distribution network than that of PluroGen Therapeutics. These are also possessed by very few firms in the industry.
Imitable
- The financial resources of PluroGen Therapeutics are costly to imitate as identified by the PluroGen Therapeutics VRIO Analysis. These resources have been acquired by the company through prolonged profits over the years. New entrants and competitors would require similar profits for a long period of time to accumulate these amounts of financial resources.
- The local food products are not that costly to imitate as identified by the VRIO Analysis of PluroGen Therapeutics. These can be acquired by competitors as well if they invest a significant amount in research and development. These also do not require years long experience. Therefore, the local food products by PluroGen Therapeutics provide it with a temporary competitive advantage that competitors can too acquire in the long run.
- The employees of PluroGen Therapeutics are also not costly to imitate as identified by the PluroGen Therapeutics VRIO Analysis. This is because other firms can also train their employees to improve their skills. These companies can also hire employees from PluroGen Therapeutics by offering better compensation packages, work environment, benefits, growth opportunities etc. This makes the employees of PluroGen Therapeutics a resource that provides a temporary competitive advantage. Competition can acquire these in the future.
- The patents of PluroGen Therapeutics are very difficult to imitate as identified by the VRIO Analysis of PluroGen Therapeutics. This is because it is not legally allowed to imitate a patented product. Similar resources to be developed and getting a patent for them is also a costly process.
- The distribution network of PluroGen Therapeutics is also very costly to imitate by competition as identified by the PluroGen Therapeutics VRIO Analysis. This has been developed over the years gradually by PluroGen Therapeutics. Competitors would have to invest a significant amount if they are to imitate a similar distribution system.
Organisation
- The financial resources of PluroGen Therapeutics are organised to capture value as identified by the VRIO Analysis of PluroGen Therapeutics. These resources are used strategically to invest in the right places; making use of opportunities and combatting threats. Therefore, these resources prove to be a source of sustained competitive advantage for PluroGen Therapeutics.
- The Patents of PluroGen Therapeutics are not well organised as identified by the PluroGen Therapeutics VRIO Analysis. This means that the organisation is not using these patents to their full potential. An unused competitive advantage exists that can be changed into a sustainable competitive advantage if PluroGen Therapeutics starts selling patented products before the patents expire.
- The distribution network of PluroGen Therapeutics is organised as identified by the VRIO Analysis of PluroGen Therapeutics. PluroGen Therapeutics uses this network to reach out to its customers by ensuring that products are available on all of its outlets. Therefore, these resources prove to be a source of sustained competitive advantage for PluroGen Therapeutics.
From the VRIO Analysis of PluroGen Therapeutics, it was identified that the financial resources and distribution network provide a sustained competitive advantage. The patents are a source of unused competitive advantage. There exists a temporary competitive advantage for employees. There exists a competitive parity for local food products. Lastly, the cost structure of PluroGen Therapeutics is a competitive disadvantage. Research and Development is also a competitive disadvantage.
Warning! This article is only an example and cannot be used for research or reference purposes. If you need help with something similar, please submit your details here.
Ishaaq Latif
5.0
My contact with this company is perfect. Received a good score.
Lilla Margita
5.0
Quite reliable and on-time service. This service is trustable. Thank you!
Mullah Durwaish
5.0
They didn't delay the paper and provided me with the right assignment that improved my CGPA. Highly recommended service!
Nelson Zeo
5.0
I got above 80% marks. I'll absolutely refer this service to all my friends. Thanks!
Next Articles
- Henry Schein: Doing Well By Doing Good? Vrio Analysis
- Global Health Partner: Obesity Care Vrio Analysis
- Embrace (D): Building The Business Model Vrio Analysis
- Schon Klinik: Eating Disorder Care Vrio Analysis
- Canadian Cancer Society: Fundraising Controversy Vrio Analysis
- British National Health Service Reform Vrio Analysis
- Liberty Medical Group (B): Crossing The Great Divide Vrio Analysis
- WuXi PharmaTech Vrio Analysis
- Integrating Private Practice And Hospital Based Breast Services At Baystate Health (Part A) Vrio Analysis
- Sydney IVF: Stem Cell Research Vrio Analysis
Previous Articles
- Cancer Care Ontario: An Innovation Strategy For Managing Wait Times Vrio Analysis
- Integrating Private Practice And Hospital Based Breast Services At Baystate Health (Part B) Vrio Analysis
- Apollo Hospitals Enterprise Ltd. Clinical Score Card Vrio Analysis
- Ledina Lushko: Navigating Health Care Delivery Vrio Analysis
- Expansion At Narayana Hrudayalaya, Video Vrio Analysis
- Challenges In Renal Care Vrio Analysis
- VisionSpring: A Lens For Growth At The Base Of The Pyramid Vrio Analysis
- Health Care Reform: 2009 2010 Vrio Analysis
- Proactive Medicare Enterprise (HK) Ltd.: Providing Healthcare In Mainland China Vrio Analysis
- Micro Labs Limited: Planning For The Future Vrio Analysis
Be a great writer or hire a greater one!
Academic writing has no room for errors and mistakes. If you have BIG dreams to score BIG, think out of the box and hire Case48 with BIG enough reputation.
Our Guarantees
Interesting Fact
Most recent surveys suggest that around 76 % students try professional academic writing services at least once in their lifetime!